Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorescein-conjugated wisteria floribunda lectin is an investigational fluorescent imaging agent developed by the University of Oxford for the detection of colorectal dysplasia, polyps, and cancer. It consists of a plant-derived lectin from *Wisteria floribunda* (WFL or WFA) chemically linked to the fluorescent dye fluorescein. The agent works by binding specifically to N-acetylgalactosamine (GalNAc)-containing glycan structures that are differentially expressed on the surface of abnormal colorectal tissues compared to healthy mucosa. During endoscopy or surgery, the agent is applied topically to the colon; subsequent illumination with a specific wavelength of light causes the bound lectin to fluoresce, allowing clinicians to identify and delineate dysplastic or malignant lesions in real-time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorescein-conjugated wisteria floribunda lectin.